Table 4:
Univariate analyses for relapse free and overall survival after propensity score matching*.
| RFS | OS | |||||
|---|---|---|---|---|---|---|
| Variable | HR | 95%CI | p | HR | 95%CI | p |
| Age | 0.99 | 0.96–1.02 | 0.54 | 1.01 | 0.97 , 1.05 | 0.66 |
| Log (WBC) at diagnosis | 0.97 | 0.65–1.47 | 0.90 | 1.05 | 0.69–1.60 | 0.80 |
| Log (Platelet) count at diagnosis | 1.17 | 0.62–2.19 | 0.63 | 1.00 | 0.52–1.92 | 0.99 |
| BM blast at diagnosis | 1.00 | 0.98–1.02 | 0.97 | 1.00 | 0.98–1.02 | 0.96 |
| Cytogenetics at diagnosis (Diploid vs. other) | 4.00 | 0.85–18.84 | 0.08 | 4.00 | 0.85–18.84 | 0.08 |
| Log (FLT3-ITD allelic ratio) at diagnosis | 0.93 | 0.62–1.37 | 0.70 | 0.92 | 0.61–1.38 | 0.68 |
| FLT3-ITD allelic ration ≥0.3 at diagnosis (Yes vs. no) | 1.40 | 0.44–4.41 | 0.57 | 1.40 | 0.44–4.41 | 0.57 |
| Presence of NPM1 mutation | ||||||
| Yes vs. no | 0.77 | 0.26–2.31 | 0.64 | 0.79 | 0.24–2.64 | 0.70 |
| Unknown vs. no | 0.67 | 0.15–3.05 | 0.61 | 0.52 | 0.10–2.63 | 0.43 |
| Year of diagnosis after 2008 (Yes vs. no) | 1.50 | 0.25–8.98 | 0.66 | 4.00 | 0.45–35.79 | 0.22 |
| Allogeneic HSCT (Yes vs. no) | 0.55 | 0.27–1.10 | 0.09 | 0.58 | 0.28–1.22 | 0.15 |
| Use of high dose cytarabine (Yes vs. no) | 0.33 | 0.03–3.20 | 0.34 | 0.33 | 0.03–3.20 | 0.34 |
*
Number of FLT3-ITD mutation and the use of FLT3 inhibitors were not analyzed for their impact on RFS and OS due to sample size<10 in groups.
Abbreviations: RFS, relapse-free survival; OS, overall survival; HR, hazard ratio; CI, confidence interval; HSCT, hematopoietic stem cell transplantation; BM, bone marrow.